Home > About Us > CNIO Publications, Year 2013 > A CNIO team discovers that three out of every four...

CNIO Publications, Year 2013

The results are published in the online version of ‘European Urology’

European Urology

A CNIO team discovers that three out of every four cases of bladder cancer display mutations in the same gene

Madrid, 9 September, 2013

The TERT gene, that codifies for the enzymatic subunit of telomerase and is a protector of genetic material, is related to ageing and carcinogenic processes

The authors propose a mutation role in the regulatory elements of this gene at early development stages of urinary bladder tumours

The results suggest the analysis of this gene in urine samples as a possible diagnostic marker for this type of tumour

Researchers from the Spanish National Cancer Research Centre (CNIO) have discovered that more than 70% of bladder tumours display somatic mutations in the TERT gene (telomerase reverse transcriptase). The TERT gene is involved in the protection of DNA and in cellular ageing processes and cancer. These results make this gene the most mutated in these tumours, which represent a serious public health problem in Spain, where the highest rates in the world are registered with 11,200 new cases each year.

The study was led by Francisco X. Real, head of the Epithelial Carcinogenesis Group at CNIO, together with Nuria Malats, the head of the Genetic & Molecular Epidemiology Group at CNIO, as well as other European groups, especially Yves Allory, a pathologist at the Mondor Hospital (Créteil, Paris, France), who is on a sabbatical year with Real and Malats’s groups at CNIO, and Ellen Zwarthoff’s group at the Erasmus Medical Centre in Rotterdam. The results are published in the online version of the journal European Urology.

The conclusions come from an exhaustive genetic and molecular study of more than 450 patients diagnosed with bladder cancer. Among the cases explored are both indolent tumours and more aggressive tumours and, therefore, those most likely to develop localised or spreading metastasis in the organism.

“When we analysed the frequency of TERT mutations in this group of patients, we observed that there was no correlation between the presence of mutations and the aggressiveness of the tumour or the survival or the patients”, says Real. The authors’ description in the article explains that: “The fact that these mutations are present in any phase of the urothelial tumoural process suggests that they occur in an early phase during carcinogenesis”.

The product of the TERT gene is a protein, the reverse transcriptase of the telomerase complex, which increases the length of telomeres, protective structures for genetic material located at the ends of chromosomes and associated with cellular ageing.

“How TERT mutations affect the length of the telomeres and encourage carcinogenesis still needs to be discovered”, says Real, adding that: “We believe that they could increase the gene expression, but additional studies are necessary”.

The authors think that the clinical implications of their study could be of great relevance, both from a diagnostic point of view and in the follow‐up treatment of these patients.

A NEW BIOMARKER

From the diagnostic and treatment-of-patients points of view, the authors propose TERT as a new biomarker for bladder cancer: “We are able to detect gene mutations in urine samples from patients, in such a way that the analysis of these mutations, combined with other markers, could be promising for the detection of the illness”.

But the consequences could go even further, due fundamentally to the fact that medicines capable of slowing down TERT activity already exist. In this case, and if future trials confirm the possibility, “we could think about the use of these inhibitors to slow down the growth of bladder cancers with these characteristics”, says Real.

Reference article:

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Yves Allory, Willemien Beukers, Ana Sagrera, Marta Flández, Miriam Marqués, Mirari Márquez, Kirstin A. van der Keur, Lars Dyrskjot, Irene Lurkin, Marcel Vermeij, Alfredo Carrato, Josep Lloreta, José A. Lorente, Enrique Carrillo-de Santa Pau, Roy G. Masius, Manolis Kogevinas, Ewout W. Steyerberg, Angela A.G. van Tilborg, Cheno Abas, Torben F. Orntoft, Tahlita C.M. Zuiverloon, Núria Malats, Ellen C. Zwarthoff, Francisco X. Real. European Urology (2013). doi: 10.1016/j.eururo.2013.08.052

Contact

  • Head of Communications
  • Nuria Noriega
  • Communications Officer
  • Cristina de Martos
  • E-mail comunicacion@cnio.es
  • Phone +(34) 917 328 000